logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Akihito Kawazoe

National Cancer Center Hospital East
H指数:38
被引数:9,322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author's Reply: Neutrophil-Macrophage Interactions in Gastric Cancer

作者回复：中性粒细胞-巨噬细胞相互作用在胃癌中的作用

Cancer Science
IF4.3
2026-08-250
OAAI
Keita H. Nagaoka; Hiroki Yamashita; Chiaki Mashima; Guoqiang Zhang; Hitoshi Saito; Tatsunori Minamide; Takuya Nakatsuru; Ryo Kamata; Shunsuke A. Sakai; Gaku Yamamoto; Tomoko Y. Morita; Kazuki Nakai; Yumi Hakozaki; Kumi Kinoshita; Yui Takahashi; Izuma Nakayama; Akihito Kawazoe; Sai M. Pulukuri; Yuko Ishii; Hiroshi Haeno; Yukie Kashima; Kohei Shitara; Tomonori Yano; Takeshi Saito; Akihiro Ohashi
Gut microbial and metabolic biomarkers for early-onset colorectal cancer

肠道微生物和代谢生物标志物用于早发性结直肠癌

Microbiome
IF12.7
2026-08-080
OA
Balqis Arche Nofinska; Sayaka Mizutani; Felix Salim; Hironori Sunakawa; Nozomu Obana; Satoshi Shiba; Kensuke Shinmura; Daisuke Kotani; Tatsuo Yachida; Hiroyuki Takamaru; Akihito Kawazoe; Yutaka Saito; Hiroaki Ikematsu; Shinji Fukuda; Shinichi Yachida; Takuji Yamada
A cDC1-NK/T-Malignant Cell Circuit Drives Immunogenic Remodeling Under PD-1 Blockade in Gastric Cancer

cDC1-NK/T-恶性细胞回路在PD-1阻断下驱动胃癌的免疫原性重塑

Cancer Science
IF4.3
2026-05-210
OAAI
Takuya Nakatsuru; Hiroki Yamashita; Chiaki Mashima; Guoqiang Zhang; Hitoshi Saito; Tatsunori Minamide; Keita H. Nagaoka; Ryo Kamata; Shunsuke A. Sakai; Gaku Yamamoto; Tomoko Y. Morita; Kazuki Nakai; Yumi Hakozaki; Kumi Kinoshita; Yui Takahashi; Izuma Nakayama; Akihito Kawazoe; Yuko Ishii; Sai M. Pulukuri; Hiroshi Haeno; Yukie Kashima; Kohei Shitara; Tomonori Yano; Takeshi Saito; Akihiro Ohashi
Neutrophil-Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo-Immunotherapy

中性粒细胞-巨噬细胞相互作用塑造化疗免疫治疗期间胃癌中炎症巨噬细胞的重塑

Cancer Science
IF4.3
2026-05-210
OAAI
Keita H. Nagaoka; Hiroki Yamashita; Chiaki Mashima; Guoqiang Zhang; Hitoshi Saito; Tatsunori Minamide; Takuya Nakatsuru; Ryo Kamata; Shunsuke A. Sakai; Gaku Yamamoto; Tomoko Y. Morita; Kazuki Nakai; Yumi Hakozaki; Kumi Kinoshita; Yui Takahashi; Izuma Nakayama; Akihito Kawazoe; Sai M. Pulukuri; Yuko Ishii; Hiroshi Haeno; Yukie Kashima; Kohei Shitara; Tomonori Yano; Takeshi Saito; Akihiro Ohashi
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial

帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌：来自随机KEYNOTE-811试验的健康相关生活质量分析

ESMO Open
IF8.3
2025-09-300
OAAI
Y.Y. Janjigian; A. Kawazoe; J. Xu; S. Lonardi; J.-P. Metges; L.S. Wyrwicz; L. Shen; Y. Ostapenko; M. Bilici; M.A. Lowery; A. Valderrama; Y. Guan; K. Li; C.-S. Shih; S.Y. Rha
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study

日本胃癌或胃食管结合部腺癌患者的一线帕博利珠单抗联合化疗：KEYNOTE-859 III期研究的亚组分析

international journal of oncology
IF2.8
2025-08-010
PRE
Hisateru Yasui; Masaki Aizawa; Kensei Yamaguchi; Akihito Kawazoe; Hiroki Hara; Masahiro Tsuda; Hirokazu Shoji; Naotoshi Sugimoto; Nobuhiro Shibata; Kenji Amagai; Yasuhiro Choda; Shiro Iwagami; Taito Esaki; Shigenori Kadowaki; Shinichi Shiratori; Shirong Han; Sonal Bordia; Kohei Shitara
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

ONO-4578 Plus Nivolumab治疗不可切除的局部晚期或复发性胃或胃食管结合部癌

Cancer Science
IF4.3
2025-07-060
OAAI
Akihito Kawazoe; Kensei Yamaguchi; Tetsuya Hamaguchi; Yukiya Narita; Shogen Boku; Takashi Oshima; Hiroki Hara; Yasuo Hamamoto; Kenji Ishido; Taito Esaki; Hisashi Hosaka; Hirofumi Yasui; Keisuke Koeda; Tomohiro Nishina; Yasushi Tsuji; Takeo Fukagawa; Masahiro Goto; Eiji Oki; Naotoshi Sugimoto; Hiroshi Matsuoka; Fumiharu Yokoyama; Tomoko Yoshida; Kazuo Yoshida; Yoshiaki Oshima; Satoru Iwasa
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

KEYNOTE-811研究的III期最终总生存数据，该研究评估了帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性、不可切除或转移性胃/胃食管结合部腺癌。

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Mahave, M.; van Cutsem, E.; Tabernero, J.; Xu, L.; Sharan, K. P.; Bhagia, P.; Janjigian, Y. Y.
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer

曲妥珠单抗deruxtecan治疗HER2-positive胃癌或胃食管交界处癌的疗效和安全性的预后和预测因素

GASTRIC CANCER
IF5.1
2024-11-020
OAAI
Jubashi, Amane; Nakayama, Izuma; Koganemaru, Shigehiro; Sakamoto, Naoya; Oda, Shioto; Matsubara, Yuki; Miyashita, Yu; Sato, Seiya; Ushiyama, Shinpei; Kobayashi, Akinori; Okazaki, Ukyo; Okemoto, Dai; Yamamoto, Kazumasa; Mishima, Saori; Kotani, Daisuke; Kawazoe, Akihito; Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Kuboki, Yasutoshi; Bando, Hideaki; Kojima, Takashi; Yoshino, Takayuki; Miyaaki, Hisamitsu; Nakao, Kazuhiko; Shitara, Kohei
An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)

一项开放标签II期研究，评估lenvatinib联合pembrolizumab和FLOT在胃及胃食管结合部腺癌患者新辅助及辅助治疗中的应用（EPOC2001）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Kawazoe, A.; Koyama, S.; Nakayama, I.; Wakabayashi, M.; Furuya, H.; Tsukamoto, K.; Tamura, H.; Ikeno, T.; Sato, A.; Kojima, M.; Kuwata, T.; Fujita, T.; Kinoshita, T.; Nishikawa, H.; Shitara, K.
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

食管胃结合部癌临床实践指南: 上消化道肿瘤峰会2023

GASTRIC CANCER
IF5.1
2024-02-226
OAAI
Kitagawa, Yuko; Matsuda, Satoru; Gotoda, Takuji; Kato, Ken; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Kawakubo, Hirofumi; Kodera, Yasuhiro; Terashima, Masanori; Muro, Kei; Takeuchi, Hiroya; Mansfield, Paul F.; Kurokawa, Yukinori; So, Jimmy; Monig, Stefan Paul; Shitara, Kohei; Rha, Sun Young; Janjigian, Yelena; Takahari, Daisuke; Chau, Ian; Sharma, Prateek; Ji, Jiafu; de Manzoni, Giovanni; Nilsson, Magnus; Kassab, Paulo; Hofstetter, Wayne L.; Smyth, Elizabeth Catherine; Lorenzen, Sylvie; Doki, Yuichiro; Law, Simon; Oh, Do-Youn; Ho, Khek Yu; Koike, Tomoyuki; Shen, Lin; van Hillegersberg, Richard; Kawakami, Hisato; Xu, Rui-Hua; Wainberg, Zev; Yahagi, Naohisa; Lee, Yeong Yeh; Singh, Rajvinder; Ryu, Min-Hee; Ishihara, Ryu; Xiao, Zili; Kusano, Chika; Grabsch, Heike Irmgard; Hara, Hiroki; Mukaisho, Ken-ichi; Makino, Tomoki; Kanda, Mitsuro; Booka, Eisuke; Suzuki, Sho; Hatta, Waku; Kato, Motohiko; Maekawa, Akira; Kawazoe, Akihito; Yamamoto, Shun; Nakayama, Izuma; Narita, Yukiya; Yang, Han-Kwang; Yoshida, Masahiro; Sano, Takeshi
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Pembrolizumab联合曲妥珠单抗和化疗治疗HER2-positive胃或胃食管交界处腺癌: 来自3期KEYNOTE-811随机安慰剂对照试验的中期分析

LANCET
IF88.5
2023-12-01120
PRE
Janjigian, Yelena Y.; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun Young
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

pembrolizumab加曲妥珠单抗和化疗治疗HER2转移性胃或胃食管交界处 (mG/GEJ) 腺癌的III期，随机，双盲，安慰剂对照的主题811研究

ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Janjigian, Y. Y.
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
ANNALS OF ONCOLOGY
IF65.4
2023-10-013
OA
Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; Van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Rha, S. Y.

研究方向

暂未获取到该数据
K
Kohei Shitara
H 指数:79论文数:1,129被引数:3.5万
T
Takayuki Yoshino
H 指数:88论文数:1,566被引数:4.9万
Y
Yasutoshi Kuboki
H 指数:32论文数:365被引数:5,937
T
Toshihiko Doi
H 指数:73论文数:830被引数:2.9万
T
Takashi Kojima
H 指数:47论文数:360被引数:1.1万
Y
Yoshiaki Nakamura
H 指数:40论文数:669被引数:9,254
D
Daisuke Kotani
H 指数:26论文数:365被引数:4,081
H
Hideaki Bando
H 指数:42论文数:595被引数:7,351
S
Saori Mishima
H 指数:19论文数:139被引数:2,150
T
Takeshi Kuwata
H 指数:47论文数:397被引数:9,732